Project Grant R43CA310454
Award Date 8/13/26
Completion Date 7/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01605, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $430,521 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop, optimize, and validate novel monoclonal antibody tools for exploring altered glycosylation in tumor cells. The recipient will develop and validate TACA-specific (tumor-associated carbohydrate antigen-specific) monoclonal antibodies targeting dysregulated glycan expression on cancer cell...
- The National Cancer Institute awarded $400,000 to Dauntless Biotherapeutics, Inc. on August 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop CD155-targeted antibody-drug conjugates for metastatic and triple-negative breast cancer. The project advances therapeutic candidates that combine direct tumor cytotoxicity with restoration of anti-tumor immunity. CD155 is expressed in over 60% of breast cancers, including triple-negative, HER2-positive, and HER2-low...
- The National Institutes of Health National Cancer Institute awarded The Washington University $399,829 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to conduct rational design of next-generation engineered T cells for enhanced cancer immunotherapy. The research addresses limited persistence of engineered T cells in cancer treatment by harnessing 4-1BB (CD137/TNFRSF9), a co-stimulatory molecule, through structure-informed protein design. Current 4-1BB chimeric...
- The National Cancer Institute awarded Health Research, Inc. (Roswell Park Division), doing business as Health Research At Roswell Park, $446,112 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct enhanced targeted therapy research for colorectal cancer. The research tests the synergistic potential of combining MAPK kinase cascade inhibitors with ribavirin, a GTP synthesis inhibitor, against BRAF- and RAS-mutated colorectal cancer. Work includes testing...
- The National Cancer Institute awarded Cytoagents Inc. $1,313,567 on September 22, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and advance CTO1681, a pharmaceutical compound designed to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy. CTO1681 is an orally available compound that reduces transcription of proinflammatory cytokines implicated in cytokine release syndrome, a severe systemic inflammatory response...
- The National Institutes of Health National Cancer Institute awarded Oncotab, Inc. $1,130,587 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct Phase II SBIR research on a bispecific antibody T-cell engager (muCD3) combined with chemotherapy for pancreatic cancer treatment. Oncotab will advance muCD3 through preclinical studies designed to de-risk its path toward first-in-human trials and commercialization. The work includes evaluating muCD3 structural...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded The Trustees of Columbia University in the City of New York $635,722 on July 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to advance probiotic-guided CAR-T cell therapy toward clinical application. The project, titled "Advancing ProCAR Therapy Toward Clinical Application," addresses limitations in current engineered cell therapies for treating solid tumors. Specifically,...
- The National Cancer Institute awarded Pearl Scientific Inc. $392,695 on September 18, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate humanized SEMA7A-antagonist monoclonal antibodies for the therapeutic treatment of breast cancer. Pearl Scientific will identify and validate humanized SEMA7A-antagonist monoclonal antibodies with high binding affinity, characterize their efficacy in blocking SEMA7A-mediated mechanisms and tumor growth, and assess their...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor regenerative cell populations and develop L1CAM-targeted antibody-drug conjugates that may overcome resistance to neoadjuvant therapy in locally advanced rectal cancer. The project will use genomic and transcriptomic analysis of pre-treatment rectal tumors, mechanistic studies in patient-derived organoid...
- The National Cancer Institute awarded Matrisome Bio, Inc. $3,481,203 on September 23, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer. Matrisome Bio is developing molecularly targeted drugs based on nanobodies that specifically target disease-associated extracellular matrix (ECM) proteins highly expressed in lung cancer and other cancer indications while minimally expressed in...